Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 113

Related Citations for PubMed (Select 24433046)

1.

Bubble liposomes and ultrasound exposure improve localized morpholino oligomer delivery into the skeletal muscles of dystrophic mdx mice.

Negishi Y, Ishii Y, Shiono H, Akiyama S, Sekine S, Kojima T, Mayama S, Kikuchi T, Hamano N, Endo-Takahashi Y, Suzuki R, Maruyama K, Aramaki Y.

Mol Pharm. 2014 Mar 3;11(3):1053-61. doi: 10.1021/mp4004755. Epub 2014 Jan 27.

PMID:
24433046
2.

A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient mdx mice.

Yin H, Moulton HM, Betts C, Seow Y, Boutilier J, Iverson PL, Wood MJ.

Hum Mol Genet. 2009 Nov 15;18(22):4405-14. doi: 10.1093/hmg/ddp395. Epub 2009 Aug 18.

3.

By-passing the nonsense mutation in the 4 CV mouse model of muscular dystrophy by induced exon skipping.

Mitrpant C, Fletcher S, Iversen PL, Wilton SD.

J Gene Med. 2009 Jan;11(1):46-56. doi: 10.1002/jgm.1265.

PMID:
19006096
4.

Morpholino oligomer-mediated exon skipping averts the onset of dystrophic pathology in the mdx mouse.

Fletcher S, Honeyman K, Fall AM, Harding PL, Johnsen RD, Steinhaus JP, Moulton HM, Iversen PL, Wilton SD.

Mol Ther. 2007 Sep;15(9):1587-92. Epub 2007 Jun 19.

PMID:
17579573
5.

In vivo comparison of 2'-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping.

Heemskerk HA, de Winter CL, de Kimpe SJ, van Kuik-Romeijn P, Heuvelmans N, Platenburg GJ, van Ommen GJ, van Deutekom JC, Aartsma-Rus A.

J Gene Med. 2009 Mar;11(3):257-66. doi: 10.1002/jgm.1288.

PMID:
19140108
6.

One-year treatment of morpholino antisense oligomer improves skeletal and cardiac muscle functions in dystrophic mdx mice.

Wu B, Xiao B, Cloer C, Shaban M, Sali A, Lu P, Li J, Nagaraju K, Xiao X, Lu QL.

Mol Ther. 2011 Mar;19(3):576-83. doi: 10.1038/mt.2010.288. Epub 2010 Dec 21.

7.

Dosing regimen has a significant impact on the efficiency of morpholino oligomer-induced exon skipping in mdx mice.

Malerba A, Thorogood FC, Dickson G, Graham IR.

Hum Gene Ther. 2009 Sep;20(9):955-65. doi: 10.1089/hum.2008.157.

PMID:
19469709
8.

[Exon-skipping therapy for Duchenne muscular dystrophy].

Takeda S.

Rinsho Shinkeigaku. 2011 Nov;51(11):914-6. Japanese.

PMID:
22277414
9.

Guanine analogues enhance antisense oligonucleotide-induced exon skipping in dystrophin gene in vitro and in vivo.

Hu Y, Wu B, Zillmer A, Lu P, Benrashid E, Wang M, Doran T, Shaban M, Wu X, Lu QL.

Mol Ther. 2010 Apr;18(4):812-8. doi: 10.1038/mt.2009.320. Epub 2010 Jan 19.

10.

[Development of an ultrasound-mediated nucleic acid delivery system for treating muscular dystrophies].

Negishi Y, Hamano N, Shiono H, Akiyama S, Endo-Takahashi Y, Suzuki R, Maruyama K, Aramaki Y.

Yakugaku Zasshi. 2012;132(12):1383-8. Review. Japanese.

11.

Antisense PMO found in dystrophic dog model was effective in cells from exon 7-deleted DMD patient.

Saito T, Nakamura A, Aoki Y, Yokota T, Okada T, Osawa M, Takeda S.

PLoS One. 2010 Aug 18;5(8):e12239. doi: 10.1371/journal.pone.0012239.

12.

In vitro evaluation of novel antisense oligonucleotides is predictive of in vivo exon skipping activity for Duchenne muscular dystrophy.

Wang Q, Yin H, Camelliti P, Betts C, Moulton H, Lee H, Saleh AF, Gait MJ, Wood MJ.

J Gene Med. 2010 Apr;12(4):354-64. doi: 10.1002/jgm.1446.

PMID:
20235089
13.

Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD.

McClorey G, Moulton HM, Iversen PL, Fletcher S, Wilton SD.

Gene Ther. 2006 Oct;13(19):1373-81. Epub 2006 May 25.

PMID:
16724091
14.

Extensive and prolonged restoration of dystrophin expression with vivo-morpholino-mediated multiple exon skipping in dystrophic dogs.

Yokota T, Nakamura A, Nagata T, Saito T, Kobayashi M, Aoki Y, Echigoya Y, Partridge T, Hoffman EP, Takeda S.

Nucleic Acid Ther. 2012 Oct;22(5):306-15. doi: 10.1089/nat.2012.0368. Epub 2012 Aug 13.

15.

Highly efficient in vivo delivery of PMO into regenerating myotubes and rescue in laminin-α2 chain-null congenital muscular dystrophy mice.

Aoki Y, Nagata T, Yokota T, Nakamura A, Wood MJ, Partridge T, Takeda S.

Hum Mol Genet. 2013 Dec 15;22(24):4914-28. doi: 10.1093/hmg/ddt341. Epub 2013 Jul 23.

16.

Dual Myostatin and Dystrophin Exon Skipping by Morpholino Nucleic Acid Oligomers Conjugated to a Cell-penetrating Peptide Is a Promising Therapeutic Strategy for the Treatment of Duchenne Muscular Dystrophy.

Malerba A, Kang JK, McClorey G, Saleh AF, Popplewell L, Gait MJ, Wood MJ, Dickson G.

Mol Ther Nucleic Acids. 2012 Dec 18;1:e62. doi: 10.1038/mtna.2012.54.

17.

Ultrasound-enhanced delivery of morpholino with Bubble liposomes ameliorates the myotonia of myotonic dystrophy model mice.

Koebis M, Kiyatake T, Yamaura H, Nagano K, Higashihara M, Sonoo M, Hayashi Y, Negishi Y, Endo-Takahashi Y, Yanagihara D, Matsuda R, Takahashi MP, Nishino I, Ishiura S.

Sci Rep. 2013;3:2242. doi: 10.1038/srep02242.

18.

Antisense mediated exon skipping therapy for duchenne muscular dystrophy (DMD).

Brolin C, Shiraishi T.

Artif DNA PNA XNA. 2011 Jan;2(1):6-15.

19.

Long-term rescue of dystrophin expression and improvement in muscle pathology and function in dystrophic mdx mice by peptide-conjugated morpholino.

Wu B, Lu P, Cloer C, Shaban M, Grewal S, Milazi S, Shah SN, Moulton HM, Lu QL.

Am J Pathol. 2012 Aug;181(2):392-400. doi: 10.1016/j.ajpath.2012.04.006. Epub 2012 Jun 7.

20.

[Exon skipping therapy for Duchenne muscular dystrophy by using antisense Morpholino].

Takeda S.

Rinsho Shinkeigaku. 2009 Nov;49(11):856-8. Review. Japanese.

PMID:
20030230
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk